Drs. Fizazi, Wallis on Updated Data from TALAPRO-2
By Karim Fizazi, MD, PhD, Christopher Wallis, MD, PhD, FRCSC - Last Updated: June 5, 2023Karim Fizazi, MD, PhD, Gustave Roussy Cancer Institute, and Christopher Wallis, MD, PhD, University of Toronto, detail the latest updates regarding the phase 3 study of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line treatment for patients with mCRPC harboring homologous recombination repair gene alterations.
The updated results of TALAPRO-2 has since led to the FDA approval of talazoparib in combination with enzalutamide for HRR-Mutated mCRPC.
Related Posts
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.
Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.